Skip to main content

Peer Review reports

From: Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma

Original Submission
26 Apr 2016 Submitted Original manuscript
Author responded Author comments
Reviewed Reviewer Report
Resubmission - Version 2
Submitted Manuscript version 2
Author responded Author comments
Resubmission - Version 3
Submitted Manuscript version 3
Author responded Author comments
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
27 Jul 2016 Editorially accepted
4 Aug 2016 Article published 10.1186/s12885-016-2633-2

You can find further information about peer review here.

Back to article page